SynAct Pharma has a combined technology portfolio that will allow the targeting inflammatory disorders with multiple modalities in with different administration methods.
The most progressed lead candidate is resomelagon, an oral drug in clinical phase 2b development. In addition SynAct is developing TXP-11, a peptide based drug, planned to be ready in 2025 to enter clinical trials.
The drugs are agonist at the melanocortin receptors, meaning that they are activating the signal pathways, controlled by the receptors, but differs in selectivity to the receptors and in which pathway they stimulate the signaling.
Our approach is to exploit these differences to develop therapies that will enable resolution of inflammation in various diseases to optimally position SynAct for the future.
| Drug | Small molecule | Peptides |
| Lead Candidate | Resomelagon (AP1189) | TXP-11 |
| Receptor Selectivity | MC receptors 1&3 | Varying profiles of MC receptors 1,3,4 & 5 No MC2R activity |
| Agonism | Biased Agonist Stimulates ERK1/2 activation pathway | Agonist Stimulates both cAMP and ERK1/2 pathways, similarly to natural agonists |
| Dosage Form | Oral, once-daily dosage form | IV, SC, injectable |